 Home > Active Ingredient News > Infection > JAMA: Among COVID-19 hospitalized patients, are IL-6 antagonists associated with 28-day all-cause mortality?

JAMA: Among COVID-19 hospitalized patients, are IL-6 antagonists associated with 28-day all-cause mortality?

 Last Update: 2021-07-29
 Source: Internet
 Author: User

Tags

tantillo auto group

order spectrum online

silicon group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The systemic excessive inflammatory response and elevated IL-6 levels caused by host immune response imbalance are related to the adverse clinical outcomes of COVID-19 hospitalized patients
.

Based on this, some randomized clinical trials have evaluated the efficacy of IL-6 antagonists on COVID-19 patients

The systemic excessive inflammatory response and elevated IL-6 levels caused by host immune response imbalance are related to the adverse clinical outcomes of COVID-19 hospitalized patients

Pixabay.
com

In order to obtain reliable efficacy data to guide clinical management, the World Health Organization (WHO) working group has developed a prospective meta-analysis program to conduct prospective meta-analysis of IL-6 antagonist treatment for patients hospitalized due to COVID-19
.

The main purpose of
the prospective meta-analysis of this randomized trial is to evaluate the relationship between the 28-day mortality rate of patients hospitalized for COVID-19 and the use of IL-6 antagonists compared with conventional treatment or placebo.

The main purpose of

The trial was confirmed through a systematic search of the electronic database from October 2020 to January 2021
.

Eligible trials randomly assigned patients hospitalized with COVID-19 to two groups.

The trial was confirmed through a systematic search of the electronic database from October 2020 to January 2021

At the end of the study, a total of 10930 patients participated in 27 trials

Correlation between IL-6 antagonist vs conventional treatment or placebo and the primary outcome of 28-day all-cause mortality

Correlation between IL-6 antagonist vs conventional treatment or placebo and the main outcome of 28-day all-cause mortality The correlation between IL-6 antagonist vs conventional treatment or placebo and the main outcome of 28-day all-cause mortality Correlation

The corresponding summary ORs of tocilizumab and sarilumab were 0.
83 and 1.
08, respectively
.

Among patients treated with corticosteroids, compared with conventional care or placebo, the ORs associated with mortality of tocilizumab and sarilumab were 0.

The corresponding summary ORs of tocilizumab and sarilumab were 0.

In summary, this prospective meta-analysis based on 27 randomized clinical trials showed that taking IL-6 antagonists 28 days after randomization was associated with a reduction in all-cause mortality

Compared with conventional care or placebo, taking IL-6 antagonists was not associated with an increased risk of infection at 28 days

Reference: The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 :A Meta-analysis .
JAMA.
Published online July 06, 2021 .
doi:10.
1001/jama.
2021.
11330 : A Meta-analysis : JAMA.
doi:10.
1001/jama.
2021.
11330 leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.